Brief: Dyadic Announces Initiation Of Dosing Of First-In-Human Phase 1 Trial To Demonstrate Clinical Safety And Antibody Response In Humans For Dyai-100 Covid-19 Recombinant Protein Rbd Booster Vaccine Candidate
24/01/2023 14:08
Jan 24 (Reuters) - Dyadic International Inc DYAI.O :
* DYADIC INTERNATIONAL INC - DOSING FOR TRIAL IS EXPECTED TO
BE
COMPLETED WITHIN Q1 OF 2023, WITH FULL STUDY REPORT BEING
AVAILABLE LATER THIS YEAR
* DYADIC ANNOUNCES INITIATION OF DOSING OF FIRST-IN-HUMAN
PHASE 1
TRIAL TO DEMONSTRATE CLINICAL SAFETY AND ANTIBODY RESPONSE IN
HUMANS FOR DYAI-100 COVID-19 RECOMBINANT PROTEIN RBD BOOSTER
VACCINE CANDIDATE
Source text for Eikon: ID:nGNX5xP8XV
Further company coverage: DYAI.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Dyadic International
See all newsDyadic International Inc reports results for the quarter ended June 30 - Earnings Summary
Dyadic International Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Dyadic International - Develops C1 Cell Lines And Manufactures Bundibugyo Ebolavirus Antigens Within 15 Days
Brief: Dyadic Announces Continued Listing On The Nasdaq Capital Market
Brief: Dyadic And Scripps Research Collaborate On Rapid-Response Hantavirus Antibody And Vaccine Development